Testosterone therapy in erectile dysfunction

Aging Male

Volumn 7, Issue 4, 2004, Pages 312-318

  Shabsigh, R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Erectile dysfunction; Hypogonadism; Nitric oxide; Sildenafil; Symptomatic late onset hypogonadism; Testogel ; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; APOMORPHINE; CALCIUM; CELL MEMBRANE PROTEIN; CYCLIC AMP; CYCLIC GMP; DNA; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PAPAVERINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SILDENAFIL; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE;

ANDROGEN THERAPY; CASTRATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; GEL; HORMONAL THERAPY; HUMAN; HYPOGONADISM; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; SCORING SYSTEM; SEXUAL FUNCTION; SKIN IRRITATION; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE;

ANDROGENS; DRUG THERAPY, COMBINATION; GELS; HUMANS; HYPOGONADISM; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; TESTOSTERONE;

EID: 11244337568     PISSN: 13685538     EISSN: None     Source Type: Journal    
DOI: 10.1080/13685530400016540     Document Type: Conference Paper

References (34)

1. Vermeulen A. Andropause. Maturitas 2000;34:5-15
2. Laumann E, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. J Am Med Assoc 1999;281:537-44
3. NIH Consensus Development Panel on Impotence: impotence. J Am Med Assoc 1993;270:83-90
4. Rosen RC, Seidman SN, Menza MA, et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004;16:334-40
5. Turner LA, Althof SE, Levine SB, et al. Self-injection of papaverine and phentolamine in the treatment of psychogenic impotence. J Sex Marital Ther 1989;15:163-76
6. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and physiological correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
7. Shabsigh R. Hypogonadism and erectile dysfunction: the role of testosterone therapy. Int J Impot Res 2003;15(Suppl 4):S9-13
8. Morley J. Impotence. Am J Med 1986;80:897-906
9. Mills T, Wiedmeier V, Stopper V. Androgen maintenance of erectile function in the rat penis. Biol Reprod 1992;46:342-8
10. Mills T, Stopper V, Wiedmeier V. Effects of castration and androgen replacement on the hemodynamics of penile erection in the rat. Biol Reprod 1994;51:234-8
11. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol 1997;15:21-6
12. Shabsigh R, Raymond JF, Olsson CA, O'Toole K, Buttyan R. Androgen induction of DNA synthesis in the rat penis. Urology 1998;52:723-8
13. Klein LT, Miller MI, Buttyan R, et al. Apoptosis in the rat penis after penile denervation. J Urol 1997;158:626-30
14. Andersson KE, Holmquist F. Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J Urol 1994;12:249-61
15. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995;52:485-9
16. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J Androl 1997;18:110-15
17. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9
18. Reilly CM, Lewis RW, Stopper VS, Mills TM. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J Androl 1997;18:588-94
19. Baba K, Yajima M, Carrier S, et al. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis. BJU Int 2000;85:953-8
20. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997;158:1764-7
21. Jain P, Rademaker A, McVary K. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000;164:371-5
22. Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996;155:1604-8
23. Findlay J, Place V, Snyder P. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989;68:369-73
24. Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986;2:943-6
25. Korenman SG, Viosca S, Garza D, et al. Androgen therapy of hypogonadal men with transscrotal testosterone systems. Am J Med 1987;83:471-8
26. Ahmed SR, Boucher AE, Manni A, Santen RJ, Bartholomew M, Deniers LM. Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab 1988;66:546-51
27. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78
28. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study. J Clin Endocrinol Metab 1996;81:1832-40
29. Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin Endocrinol (Oxf) 1999;50:57-62
30. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-10
31. Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000;85:2839-53
32. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site vs four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000;85:964-9
33. Shabsigh R, Kaufman J, Steidle J, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63
34. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8